Frakefamide

Drug Profile

Frakefamide

Alternative Names: BCH 3963; LEF; LEF 576; SPD 759

Latest Information Update: 25 Jun 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shire Pharmaceuticals Group
  • Class Analgesics
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 20 Sep 2001 AstraZeneca discontinued development of frakefamide with rights transferred back to Shire Pharmaceuticals
  • 31 Jul 2001 AstraZeneca offers the rights for frakefamide back to Shire Pharmaceuticals
  • 05 Jun 2001 BioChem Pharma has been acquired by Shire Pharmaceuticals Group
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top